The Global Lung Cancer Diagnostic Tests Market is estimated at

0

Covina, April 19, 2022 (GLOBE NEWSWIRE) — Lung cancer starts in the lungs and can spread to lymph nodes or other organs in the body, including the brain. Cancer that has progressed to other organs can potentially spread to the lungs. Metastasis is the spread of cancer cells from one organ to another. Small cell and non-small cell lung tumors are the two most common types of lung cancer. These types of lung cancer grow and respond to treatment in different ways. According to the American Cancer Society, non-small cell lung cancer is more common than small cell lung cancer. Symptoms of lung cancer vary from person to person. Lung symptoms affect some people.

Analysis of the region:

North America dominates the lung cancer diagnostics market, owing to the rising incidence of lung cancer and aging population in this particular region. North America is considered as the largest regional market with the highest market share owing to increasing invasion rates of the technologically advanced products market, increased patient awareness, and increasing smoking prevalence levels in the region, all of which contribute to the larger market share in the region. Due to the increased use of lung cancer diagnostics due to the increase in smoking in the region, Asia-Pacific (APAC) is expected to experience considerable growth during the projection period.

Request a free sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4863

Key development:

  • AnPac ​​Bio-Medical Science Co., Ltd, a biotechnology company focused on cancer screening and early detection with operations in China and the United States, announced on January 25, 2021 that the Chinese regulatory authority of Medical Products, the National Medical Products Administration, had approved AnPac ​​Bio to begin registration testing of its class III lung cancer diagnostic ancillary medical device at a designated medical device testing laboratory, which is a sign of progress.
  • Amgen established significant partnerships with renowned diagnostic companies Guardant Health, Inc. and QIAGEN NV in January 2020 to develop companion blood- and tissue-based (CDx) diagnostics for the investigational cancer treatment AMG 510, respectively. AMG 510 is the first KRASG12C inhibitor to come to the clinic, where it will be studied in the treatment of various types of tumors. In human cancer, KRAS G12C is one of the most frequently mutated oncogenes. CDx tests for non-small cell lung cancer will be the focus of agreements with the two companies initially (NSCLC).

For upcoming trends and ideas prevailing in this market, click on the link below:

Links- https://www.prophecymarketinsights.com/market_insight/Global-Lung-Cancer-Diagnostic-Test-Market-4863

Segmentation:

The global lung cancer diagnostic tests market was worth US$1.98 billion in 2020 and is estimated to be worth US$4.07 billion by 2030 and is expected to register a CAGR of 7.50%. The global lung cancer diagnostic test market is segmented by test type, cancer type, end-use industry and region.

  • By type of test, the global lung cancer diagnostic test market is segmented into biomarker test (EGFR mutation test, KRAS mutation test, ALK test, HER2 test, others), imaging test (computed tomography (CT ), positron emission tomography (PET) scanner, chest X-ray, others), biopsy (needle biopsy, bronchoscopy biopsy, open biopsy, others.
  • By type of cancer, the global lung cancer diagnostic test market is categorized into non-small cell lung cancer and small cell lung cancer.
  • By end-use industry, the global lung cancer diagnostic testing market is categorized into hospital laboratories, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
  • By region, the global lung cancer diagnostic test market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Competitive analysis:

Key players operating in the global lung cancer diagnostic tests market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd. , Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.

Report Scope:

  1. Global Lung Cancer Diagnostic Tests Market, By Test Type, 2020-2030, (USD Million)
    • Insight
      • Market Value & Forecast (USD Million) & Share Analysis (%), 2020 – 2030
      • Annual Growth Analysis (%), 2020 – 2030
      • Industry trends
    • Biomarker test
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Imaging test
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Biopsy
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
  2. Global Lung Cancer Diagnostic Tests Market, by Application, 2020-2030, (USD Million)
    • Insight
      • Market Value & Forecast (USD Million) & Share Analysis (%), 2020 – 2030
      • Annual Growth Analysis (%), 2020 – 2030
      • Industry trends
    • Non-small cell lung cancer
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Small cell lung cancer
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
  3. Global lung cancer diagnostic tests market, by end-use industry, 2020-2030, (USD Million)
    • Insight
      • Market Value & Forecast (USD Million) & Share Analysis (%), 2020 – 2030
      • Annual Growth Analysis (%), 2020 – 2030
      • Industry trends
    • Associated hospital laboratories
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Independent diagnostic laboratories
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Diagnostic Imaging Centers
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Cancer research centers
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030
    • Others
      • Insight
      • Market Size & Forecast (Million US$) & Annual Growth (%), 2020-2030

For customization: https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/4863

About Prophecy Market Insights

Prophecy Market Insights is market research, analysis, marketing/business strategy and custom solutions that provides strategic and tactical support to clients to make informed business decisions and identify and realize high value opportunities in areas of… target activity. We also help our clients solve business challenges and provide the best solutions to overcome them and transform their business.
Here are some of the key points addressed by this market report:

  • Describe a review of the product portfolio, including product development, planning and positioning
  • Describes details of key operational strategies, focusing on R&D strategy, corporate structure, localization strategy, manufacturing capabilities, and financial performance of various companies.
  • Detailed analysis of market earnings over the forecast period.
  • Examine various market perspectives using Porter’s five forces analysis, PEST and SWOT analysis.
  • Examine the segments that are expected to dominate the market.
  • Study the regional analysis which is expected to register the highest growth during the forecast period.

Browse related reports:

  1. Global Cancer Diagnostics Market, By Method (Enzyme Immunoassay (ELISA), Fluorescent Enzyme-Linked Assay (ELFA), Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunohistochemistry, Microarray, imaging, magnetic resonance imaging (MRI), computed tomography (CT scan), positron emission tomography (PET), ultrasound, mammography, biopsy and others), by indication of disease (breast cancer, colorectal cancer, cervical cancer cancer, lung cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, liver cancer, pancreatic cancer, ovarian cancer and others) and by region (North America , Europe, Asia-Pacific, Latin America, Middle East and Africa) – Trends, Analysis and Forecasts to 2030
  2. Global Next Generation Cancer Diagnostics Market, By Technology (RT-PCR, Next Generation Sequencing, DNA Chip, Lab-on-Chip and Others), By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer) , Colorectal Cancer and Others), By Application (CTC Analysis, Biomarker, Proteomic Analysis and Others) and Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) – Trends, Analysis and Forecast of the market until 2030

        
Share.

Comments are closed.